Anticorps Monoclonal anti-VEGFR2/KDR

VEGFR2/KDR Monoclonal Antibody for WB, ELISA

Hôte / Isotype

Mouse / IgG1

Réactivité testée

Humain

Applications

WB, IHC, IF, ELISA

Conjugaison

Non conjugué

Publications(10)

CloneNo.

1G2A8

N° de cat : 67407-1-Ig

Synonymes

KDR, VEGFR2, Protein-tyrosine kinase receptor flk-1, FLK-1, EC:2.7.10.1

---

Galerie de données de validation

• 

  WB analysis of human placenta using 67407-1-Ig

  human placenta tissue were subjected to SDS PAGE followed by western blot with 67407-1-Ig (VEGFR2 antibody) at dilution of 1:4000 incubated at room temperature for 1.5 hours.

---

Applications testées

• Résultats positifs en WB: tissu placentaire humain,

Dilution recommandée

• Western Blot (WB): WB : 1:1000-1:8000

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, check data in validation data gallery

Applications publiées

• WB: See 7 publications below
• IHC: See 1 publications below
• IF: See 3 publications below
• FC: See 1 publications below

Informations sur le produit

67407-1-Ig cible VEGFR2/KDR dans les applications de WB, IHC, IF, ELISA et montre une réactivité avec des échantillons Humain

• Réactivité: Humain
• Réactivité citée: Humain
• Hôte / Isotype: Mouse / IgG1
• Clonalité: Monoclonal
• Type: Anticorps
• Immunogène: VEGFR2/KDR Protéine recombinante Ag24589
• Nom complet: kinase insert domain receptor (a type III receptor tyrosine kinase)
• Masse moléculaire calculée: 1356 aa, 152 kDa
• Poids moléculaire observé: 230 kDa
• Numéro d’acquisition GenBank: BC131822
• Symbole du gène: KDR
• Identification du gène (NCBI): 3791
• Conjugaison: Non conjugué
• Forme: Liquide
• Méthode de purification: Purification par protéine G
• Tampon de stockage: PBS with 0.02% sodium azide and 50% glycerol
• Conditions de stockage: Stocker à -20°C. Stable pendant un an après l'expédition. L'aliquotage n'est pas nécessaire pour le stockage à -20^oC Les 20ul contiennent 0,1% de BSA.

Informations générales

KDR, also named as VEGFR-2, FLK1 and CD309, is a receptor for VEGF or VEGFC. KDR which belongs to the protein kinase superfamily, has a tyrosine-protein kinase activity. The VEGF-kinase ligand/receptor signaling system plays a key role in vascular development and regulation of vascular permeability. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions. KDR functions as the main mediator of VEGF-induced endothelial proliferation, survival, migration, tubular morphogenesis and sprouting. Mutations of this gene are implicated in infantile capillary hemangiomas.

Publications

Species	Application	Title
human	IF	Talanta; Dynamics of endothelial cells migration in nature-mimicking blood vessels; Authors - Yang Du
human	WB	Front Oncol; An Essential NRP1-Mediated Role for Tagln2 in Gastric Cancer Angiogenesis.; Authors - Hongwei Jin
human	WB	Front Genet; ANLN and KDR Are Jointly Prognostic of Breast Cancer Survival and Can Be Modulated for Triple Negative Breast Cancer Control.; Authors - Xiaofeng Dai
human	WB	Arch Pharm (Weinheim); Design, synthesis, and biological evaluation of naphthalene imidazo[1,2-b]pyridazine hybrid derivatives as VEGFR selective inhibitors; Authors - Shuang Wang
		Adv Mater; Personalized Vascularized Tumor Organoid-on-a-Chip for Tumor Metastasis and Therapeutic Targeting Assessment; Authors - Yang Du
human	IHC,IF	Cell Tissue Res; A histological study of vascular wall resident stem cells in venous malformations; Authors - Hou-Fu Xia

{{ptg:RelatedPrimaryAntibodies}}